BP fires its chairman, Boeing fires up production

🔔 After the Bell

🎯 Session Review

Wednesday, May 27 was one of those sessions where the headlines were louder than the scoreboard. The S&P 500 crept up just 0.02% to 7,520.36, the Nasdaq added 0.07% to 26,674.73, and the Dow led the pack with a respectable 0.36% gain to 50,644.28. Not exactly a fireworks show, but the market held its ground.

Behind the calm surface, there was plenty happening across sectors. Corporate governance drama at BP, a fresh FDA approval for AbbVie, and a production ramp at Boeing gave investors real stories to chew on. Treasury yields ticked down a hair across the curve, with the 10-year sitting at 4.48%, providing a mild tailwind for equities.

Bitcoin slipped 1.02% to $75,053, a reminder that not everything participated in the day's quiet optimism. The dollar index nudged up to 99.21, holding its footing without making a dramatic move either way.

Millionaire warns: Move your money ASAP [ad]

📊 Today's Market Movers

▲ Gainers DY ▲ +25.95% LUNR ▲ +15.72% IREN ▲ +13.48% MANU ▲ +12.81% PENN ▲ +11.9%

▼ Losers ZS ▼ -31.52% WOLF ▼ -14.08% BRAI ▼ -13.61% BSX ▼ -12.53% PDD ▼ -10.38%

🚀 Key Catalysts

The energy sector had some internal turbulence today. BP ousted its chairman Albert Manifold in what is becoming a genuinely unsettling pattern of leadership instability at the oil giant. Meanwhile, Chevron shareholders voted down a proposal to separate the board chair and CEO roles at their annual meeting, choosing continuity over structural change. Two very different outcomes for two major energy names.

On the industrial and aerospace front, Boeing provided a genuine bright spot. CEO Kelly Ortberg confirmed the company is bumping 737 production from 42 to 47 jets per month following conversations with the FAA. That kind of operational momentum matters after years of Boeing navigating quality and regulatory headwinds. BA investors had reason to feel decent about that update.

In healthcare, AbbVie scored an FDA approval for its treatment targeting blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer. It is a niche market by definition, but FDA wins build pipeline credibility, and ABBV has been working hard to diversify beyond its legacy Humira business.

Trump’s “Ace Card” For Iran [ad]

I paid $5,000 to hear Elon say this

🎭 Investor Mood

Today's mood was cautiously constructive, which is a fancy way of saying nobody panicked and a few people actually smiled. Bank of America CEO Brian Moynihan delivered a confident outlook, projecting 15% growth in Q2 trading revenue compared to the same period last year. That kind of forward guidance from a major financial institution tends to keep sentiment anchored.

On the flip side, PDD Holdings, the Chinese parent of Temu, reported a first-quarter profit miss amid brutal competition back home. With trade dynamics between the US and China still a live wire, that earnings stumble added a small note of caution around Chinese consumer names. The US-Mexico trade talks, notably excluding Canada, added another layer of geopolitical texture to the day.

The FAA ordering SpaceX to investigate its Starship booster crash landing was a reminder that even the most ambitious tech ventures hit speed bumps. It did not crater the broader sentiment, but it underscored that regulatory friction is not going away for anyone, not even Elon Musk.

This is going to blow up our economy. Could be worse than 2008. [ad]

🔍 5 Focus Points for Tomorrow

🍎	Boeing production ramp: Watch BA for follow-through after the 737 output increase news from CEO Kelly Ortberg

⛽	AbbVie FDA catalyst: Monitor ABBV for investor reaction to the rare blood cancer drug approval and what it means for the pipeline

📋	Zscaler selloff fallout: ZS dropped nearly $58 in a single session, watch for analyst commentary and any earnings-related explanation

🌍	US-Mexico trade talks: Three negotiation rounds are beginning without Canada, watch EWW and EWC for ETF-level reaction

📋	META momentum: Shares up over $22 today, keep tracking whether AI-driven ad revenue optimism continues to push the stock toward new highs

The real reason Musk, Huang, Cook, and Fink just flew to Beijing

💸 Bottom Line

A few names are worth watching closely as this week wraps up. Zscaler was the most notable casualty in trending stocks, dropping nearly $58 to $126.41. That kind of single-session move in a cybersecurity name demands attention, and earnings or guidance commentary is likely the culprit. Meanwhile, META surged over $22 to $635.26, a strong move that reinforces the AI advertising thesis still running hot under the surface.

OpenAI's nonprofit arm pledged $250 million to help workers and economies adapt to AI disruption. It is a headline that sounds philanthropic but signals something broader: even the architects of AI disruption are acknowledging the economic reshaping that is already underway. That is worth sitting with for a moment.

Gucci partnering with Renault's Alpine F1 team starting in 2027 is the kind of luxury-meets-motorsport story that feels frivolous until you realize how much brand capital is moving into that space. Keep an eye on PPRUY and RNLSY for any momentum that story generates. Tomorrow, watch Boeing, AbbVie, and any further trade development between the US and Mexico.

Private interview with the most connected man in Washington [ad]